What happened in optometry this week: February 5-February 9

Blog
Article

Catch up on what happened in optometry during the week of February 5-February 9.

Catch up with what Optometry Times shared this week:

FDA accepts IND for OK-101 for neuropathic corneal pain

By Emily Kaiser Maharjan, Assistant Managing Editor

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

Read here...

UC optometrists strike over “bad-faith” bargaining practices, protest low salaries

By Jordana Joy, Associate Editor

Members of the University Professional and Technical Employees CWA Local 9119 drew picket lines on February 6 and 7 to protest unfair labor and bargaining practices upheld by University of California.

Read here...

Gaps in vision screening for school-aged children uncovered in study

By Lynda Charters

A new study found that only a little over half of school-aged children participants underwent vision screening within the past two years, highlighting gaps in eye care access.

Read here...

Diagnosing and treating Demodex blepharitis

By Amy Nau, OD, Dipl CCLRT; Lynda Charters

Everything, no matter how minute, has a purpose and so that must also be the case for the pesky Demodex mite, the infective parasites that lie between or on the eyelashes in highly sebaceous areas. Some researchers think these parasites may help control bacterial populations through their acidic secretions. However, their waste can cause inflammation and hypersensitivity reactions in affected individuals.

Read here...

ALSTAR study identifies potential functional biomarker for early, intermediate AMD

By Lynda Charters

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

Read here...

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.